8,000 Shares in ARK Genomic Revolution ETF (BATS:ARKG) Acquired by Zuckerman Investment Group LLC

Zuckerman Investment Group LLC purchased a new stake in ARK Genomic Revolution ETF (BATS:ARKG) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 8,000 shares of the company’s stock, valued at approximately $188,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. JPMorgan Chase & Co. increased its holdings in ARK Genomic Revolution ETF by 31.0% in the third quarter. JPMorgan Chase & Co. now owns 2,955,279 shares of the company’s stock worth $75,655,000 after purchasing an additional 698,701 shares in the last quarter. Atria Wealth Solutions Inc. lifted its holdings in ARK Genomic Revolution ETF by 121.1% during the 4th quarter. Atria Wealth Solutions Inc. now owns 19,792 shares of the company’s stock worth $466,000 after purchasing an additional 10,841 shares in the last quarter. Sanctuary Advisors LLC bought a new stake in ARK Genomic Revolution ETF during the fourth quarter valued at $401,000. Raymond James Financial Inc. bought a new position in ARK Genomic Revolution ETF in the fourth quarter valued at $2,027,000. Finally, Barclays PLC increased its holdings in shares of ARK Genomic Revolution ETF by 252.7% in the third quarter. Barclays PLC now owns 285,108 shares of the company’s stock worth $7,299,000 after buying an additional 204,283 shares during the period.

ARK Genomic Revolution ETF Stock Performance

Shares of BATS:ARKG opened at $20.56 on Thursday. The stock’s 50-day moving average is $23.98 and its 200 day moving average is $24.58. ARK Genomic Revolution ETF has a 1 year low of $17.51 and a 1 year high of $31.16.

ARK Genomic Revolution ETF Company Profile

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.